Clinical Trial

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Study acronym: PTC-IMPACT
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-18; most recent amendment 2026-01-14.
Status change: Not Yet Recruiting → Recruiting 2024-04-17
Trial Details
NCT Number NCT06227728
Lead Sponsor Gene Solutions
Conditions Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Advanced Cancer, Immune Checkpoint Inhibitor
Enrollment 50 participants
Start Date 2024-03-22
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-16